This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integra Divests Assets to Natus, Paves Way for Codman Buyout
by Zacks Equity Research
Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.
Achillion's HCV Partnership with J&J Terminated, Stock Falls
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) suffered a setback as Janssen terminated their worldwide license and collaboration arrangement on hepatitis C.
3 Excellent Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 Dividend ETFs for your portfolio to battle market uncertainty.
Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval
by Swarup Gupta
The Dow endured significant losses over a holiday-shortened trading week.
MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails
by Zacks Equity Research
Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.
J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.
The Zacks Analyst Blog Highlights: Johnson & Johnson, JPMorgan, Microsoft, Motorola, J.M. Smucker and Entergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, JPMorgan, Microsoft, Motorola, J.M. Smucker and Entergy
Pfizer Presents Encouraging Eliquis Results in NVAF Patients
by Zacks Equity Research
Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.
Biogen Alzheimer's Drug Shows Promise in Long-Term Study
by Zacks Equity Research
Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.
Company News For August 29, 2017
by Zacks Equity Research
Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ
J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III
by Zacks Equity Research
J&J's (JNJ) blood thinner Xarelto shows a significant risk reduction in major cardiovascular events in patients with stable coronary and peripheral artery disease.
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
by Zacks Equity Research
The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
by Zacks Equity Research
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.
Catalyst (CPRX) Focused on Development of Pipeline Candidates
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.
Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More
by Zacks Equity Research
A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.
Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales
by Zacks Equity Research
Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.
Key FDA Events to Watch Out for in Aug 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company
Dow 30 Stock Roundup: Caterpillar, DuPont, MCD, P&G Beat
by Swarup Gupta
The Dow enjoyed a strong week of gains, riding on stellar earnings results.
AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact
by Zacks Equity Research
AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
by Zacks Equity Research
United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.